-+ 0.00%
-+ 0.00%
-+ 0.00%

Anixa Biosciences Partners With Curia on Breast Cancer Vaccine Formulation for Phase 2 Trial

PUBT·11/18/2026 13:27:06
Diffusion vocale
Anixa Biosciences Partners With Curia on Breast Cancer Vaccine Formulation for Phase 2 Trial
  • Anixa Biosciences will collaborate with Curia to develop its breast cancer vaccine formulation for an upcoming Phase 2 trial.
  • Formulation development will target stability and manufacturing scalability to support future clinical studies and potential commercial production.
  • The vaccine, developed with Cleveland Clinic, met primary endpoints in a 35-woman Phase 1 trial; 74% showed protocol-defined immune responses.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611180825PR_NEWS_USPR_____LA00738) on November 18, 2026, and is solely responsible for the information contained therein.